Lancet-话题@MedSci

#Lancet#

4453篇内容 | 15532人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1831346, encodeId=83491831346a1, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？, objectType=article, longId=219170, objectId=015e2191e0a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=015e2191e0a9, replyNumber=0, likeNumber=116, createdTime=2021-11-28, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=015e2191e0a9, moduleTitle=Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=015e2191e0a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831213, encodeId=bd65183121375, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！, objectType=article, longId=212817, objectId=1b8121281e7b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b8121281e7b, replyNumber=0, likeNumber=84, createdTime=2021-10-27, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b8121281e7b, moduleTitle=Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b8121281e7b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831068, encodeId=ae7b1831068c0, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：1990-2019全球听力受损患病率研究, objectType=article, longId=208340, objectId=0b6920834062, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b6920834062, replyNumber=0, likeNumber=92, createdTime=2021-07-22, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b6920834062, moduleTitle=Lancet：1990-2019全球听力受损患病率研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b6920834062)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831103, encodeId=e37118311031e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期, objectType=article, longId=209579, objectId=b43d2095e9ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b43d2095e9ba, replyNumber=0, likeNumber=157, createdTime=2022-03-13, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b43d2095e9ba, moduleTitle=Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b43d2095e9ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831285, encodeId=d18a1831285b4, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：全球半数病例在中国，K药为食管癌患者带来好消息！, objectType=article, longId=216447, objectId=c37e21644ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c37e21644ef7, replyNumber=0, likeNumber=92, createdTime=2022-04-19, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c37e21644ef7, moduleTitle=Lancet：全球半数病例在中国，K药为食管癌患者带来好消息！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c37e21644ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831179, encodeId=01c418311e9de, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：每日1次Upadacitinib单药治疗可显著改善中重度特应性皮炎患者临床症状, objectType=article, longId=211663, objectId=c26d2116637e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c26d2116637e, replyNumber=0, likeNumber=100, createdTime=2021-07-18, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c26d2116637e, moduleTitle=Lancet：每日1次Upadacitinib单药治疗可显著改善中重度特应性皮炎患者临床症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c26d2116637e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831248, encodeId=4f2b1831248b2, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Respir Med：周彩存教授团队发表埃克替尼术后辅助靶向研究数据（EVIDENCE研究）, objectType=article, longId=214475, objectId=5bd72144e5cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5bd72144e5cc, replyNumber=0, likeNumber=94, createdTime=2021-09-16, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5bd72144e5cc, moduleTitle=Lancet Respir Med：周彩存教授团队发表埃克替尼术后辅助靶向研究数据（EVIDENCE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5bd72144e5cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831087, encodeId=08f3183108edf, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Gastroenterol Hepatol:关注炎性肠病患者焦虑抑郁，改善预后, objectType=article, longId=209104, objectId=88cd2091046b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88cd2091046b, replyNumber=0, likeNumber=110, createdTime=2021-08-06, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88cd2091046b, moduleTitle=Lancet Gastroenterol Hepatol:关注炎性肠病患者焦虑抑郁，改善预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88cd2091046b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831335, encodeId=ec621831335d1, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：人工智能重新定义，倍他乐克是治疗年轻房颤心衰患者的“基石”！, objectType=article, longId=218929, objectId=dba82189299a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dba82189299a, replyNumber=0, likeNumber=108, createdTime=2021-12-09, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dba82189299a, moduleTitle=Lancet：人工智能重新定义，倍他乐克是治疗年轻房颤心衰患者的“基石”！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dba82189299a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831352, encodeId=04271831352bd, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Neurol：难分伯仲——非免疫原性重组葡激酶与阿尔替普酶治疗急性缺血性卒中患者的比较(FRIDA), objectType=article, longId=219166, objectId=7d30219166f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d30219166f5, replyNumber=0, likeNumber=103, createdTime=2021-12-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d30219166f5, moduleTitle=Lancet Neurol：难分伯仲——非免疫原性重组葡激酶与阿尔替普酶治疗急性缺血性卒中患者的比较(FRIDA), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d30219166f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831143, encodeId=a20b183114368, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Oncol：癌症患者能接种新冠疫苗吗？接种效果如何？, objectType=article, longId=210594, objectId=0eaa2105942c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0eaa2105942c, replyNumber=0, likeNumber=92, createdTime=2021-10-04, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0eaa2105942c, moduleTitle=Lancet Oncol：癌症患者能接种新冠疫苗吗？接种效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0eaa2105942c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831144, encodeId=9937183114459, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=LANCET：彻底消除SARS-CoV-2才能为健康、经济和公民自由创造更佳结果, objectType=article, longId=210666, objectId=8b8b21066689, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b8b21066689, replyNumber=0, likeNumber=0, createdTime=2022-03-03, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b8b21066689, moduleTitle=LANCET：彻底消除SARS-CoV-2才能为健康、经济和公民自由创造更佳结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b8b21066689)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831300, encodeId=88c8183130020, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期, objectType=article, longId=217099, objectId=442f21e09939, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=442f21e09939, replyNumber=0, likeNumber=101, createdTime=2022-04-18, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=442f21e09939, moduleTitle=Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=442f21e09939)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831395, encodeId=d82b18313953e, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：经皮冠状动脉介入治疗发生造影剂相关急性肾损伤的风险评估, objectType=article, longId=220555, objectId=d9cb22055556, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9cb22055556, replyNumber=0, likeNumber=116, createdTime=2022-04-09, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9cb22055556, moduleTitle=Lancet：经皮冠状动脉介入治疗发生造影剂相关急性肾损伤的风险评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9cb22055556)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831119, encodeId=4b0f183111917, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Oncol：派姆单抗辅助治疗可显著提高晚期高危黑色素瘤的长期无远处复发存活率！, objectType=article, longId=209912, objectId=e3e920991243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3e920991243, replyNumber=0, likeNumber=87, createdTime=2021-11-26, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3e920991243, moduleTitle=Lancet Oncol：派姆单抗辅助治疗可显著提高晚期高危黑色素瘤的长期无远处复发存活率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3e920991243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831308, encodeId=e27b183130859, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：切除的IB–IIIA期NSCLC患者辅助化疗后应用阿特珠单抗可额外获益, objectType=article, longId=217404, objectId=357521e404f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=357521e404f2, replyNumber=0, likeNumber=80, createdTime=2022-04-16, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=357521e404f2, moduleTitle=Lancet：切除的IB–IIIA期NSCLC患者辅助化疗后应用阿特珠单抗可额外获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=357521e404f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831152, encodeId=31bd1831152d0, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet：17万人数据——减肥手术将使肥胖患者死亡率减半，寿命延长6年！, objectType=article, longId=211014, objectId=27d1211014b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27d1211014b8, replyNumber=0, likeNumber=126, createdTime=2022-02-10, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27d1211014b8, moduleTitle=Lancet：17万人数据——减肥手术将使肥胖患者死亡率减半，寿命延长6年！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27d1211014b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831067, encodeId=a9d3183106e6d, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Neurology：八种院前卒中量表检测疑似卒中患者颅内大血管闭塞的比较：一项前瞻性观察研究, objectType=article, longId=208330, objectId=b9d0208330f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9d0208330f4, replyNumber=0, likeNumber=77, createdTime=2021-12-20, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9d0208330f4, moduleTitle=Lancet Neurology：八种院前卒中量表检测疑似卒中患者颅内大血管闭塞的比较：一项前瞻性观察研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9d0208330f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831263, encodeId=cc1f1831263f0, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Oncol：抗PD-L1抗体Avelumab是否可用于卵巢癌的一线治疗？, objectType=article, longId=215475, objectId=8fb22154e583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fb22154e583, replyNumber=0, likeNumber=88, createdTime=2022-03-19, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fb22154e583, moduleTitle=Lancet Oncol：抗PD-L1抗体Avelumab是否可用于卵巢癌的一线治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fb22154e583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1831140, encodeId=1c2b183114069, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, objectTitle=Lancet Haematol：早期识别血管内皮细胞病变并减轻其进展或可改善COVID-19患者的结局, objectType=article, longId=210522, objectId=91c121052234, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91c121052234, replyNumber=0, likeNumber=69, createdTime=2022-03-02, rootId=0, userName=howi, userId=3f0227, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91c121052234, moduleTitle=Lancet Haematol：早期识别血管内皮细胞病变并减轻其进展或可改善COVID-19患者的结局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91c121052234)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Lancet

2020-05-29

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Neurol：口服脑穿透性BTK抑制剂托莱布替尼治疗复发性多发性硬化症的安全性和有效性？

2021-11-28

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet oncol：Sintilimab联合贝伐单抗生物仿制药治疗不能切除的肝癌的预后明显优于索拉非尼！

2021-10-27

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：1990-2019全球听力受损患病率研究

2021-07-22

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Oncol：积极症状控制联合FOLFOX化疗可有效延长二线治疗晚期胆道癌患者生存期

2022-03-13

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：全球半数病例在中国，K药为食管癌患者带来好消息！

2022-04-19

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：每日1次Upadacitinib单药治疗可显著改善中重度特应性皮炎患者临床症状

2021-07-18

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Respir Med：周彩存教授团队发表埃克替尼术后辅助靶向研究数据（EVIDENCE研究）

2021-09-16

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Gastroenterol Hepatol:关注炎性肠病患者焦虑抑郁，改善预后

2021-08-06

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：人工智能重新定义，倍他乐克是治疗年轻房颤心衰患者的“基石”！

2021-12-09

zhaojie88 (审核中...)

前往app查看评论内容

#Lancet#

Lancet Neurol：难分伯仲——非免疫原性重组葡激酶与阿尔替普酶治疗急性缺血性卒中患者的比较(FRIDA)

2021-12-17

zhouqu_8 (审核中...)

前往app查看评论内容

#Lancet#

Lancet Oncol：癌症患者能接种新冠疫苗吗？接种效果如何？

2021-10-04

howi (审核中...)

前往app查看评论内容

#Lancet#

LANCET：彻底消除SARS-CoV-2才能为健康、经济和公民自由创造更佳结果

2022-03-03

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Respir Med：3期| 厄洛替尼+贝伐单抗未能延长转移性EGFR突变NSCLC患者的总生存期

2022-04-18

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：经皮冠状动脉介入治疗发生造影剂相关急性肾损伤的风险评估

2022-04-09

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Oncol：派姆单抗辅助治疗可显著提高晚期高危黑色素瘤的长期无远处复发存活率！

2021-11-26

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：切除的IB–IIIA期NSCLC患者辅助化疗后应用阿特珠单抗可额外获益

2022-04-16

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet：17万人数据——减肥手术将使肥胖患者死亡率减半，寿命延长6年！

2022-02-10

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Neurology：八种院前卒中量表检测疑似卒中患者颅内大血管闭塞的比较：一项前瞻性观察研究

2021-12-20

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Oncol：抗PD-L1抗体Avelumab是否可用于卵巢癌的一线治疗？

2022-03-19

howi (审核中...)

前往app查看评论内容

#Lancet#

Lancet Haematol：早期识别血管内皮细胞病变并减轻其进展或可改善COVID-19患者的结局

2022-03-02

科室
- - 订阅+
  - 更多科室
工具
服务